ClinicalTrials.gg
WithdrawnNCT05571761Updated Jul 3, 2024

Teleneuropsychological Intervention in Asymptomatic HIV Seropositive Patients: N&C NeuroChange

An interventional study of Cognitive stimulation program in Telerehabilitation, Neuropsychology and HIV Dementia, sponsored by Universidad Nacional Autonoma de Mexico. Withdrawn at 1 site in Mexico. Open to participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Universidad Nacional Autonoma de Mexico · Not applicable, Interventional, and Supportive care

Why this study was withdrawn
experimental abandonment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2022, registered Sep 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

Currently 37.9 million people are living with human immunodeficiency virus (HIV) around the world (UNAIDS, 2018). Even with antiretroviral treatment (ART), the virus enters the central nervous system and can affect the following structures: amygdala, hippocampus, thalamus, parietal, frontal, temporal regions, orbitofrontal, cingulate, motor and sensory cortex; generating cognitive, behavioral and motor alterations, up to HIV-associated neurocognitive disorder (HAND) and occasionally HIV-associated dementia (HAD).

Few clinical studies have been conducted using computerized cognitive rehabilitation programs to counteract neuropsychological alterations. The aim of this project is to explore the feasibility of a cognitive stimulation program (CSP) developed to strengthen cognitive domains identified as impaired through a neuropsychological assessment in asymptomatic HIV+ patients adherent to ART, with the purpose of improving their quality of life and mood disorder.

Read the detailed description

A pilot randomized controlled trial (RCT) will be conducted with a study group and a control group in waiting list. This design will be used because it allows to evaluate the feasibility of a teleneuropsychological intervention (N\&C NeuroChange) and to identify a preliminary effect as a first approach in a given population, provides greater experimental control over the study variables and allows pre-intervention, post-intervention and follow-up comparisons.

Lancaster et al. (2004) state that n=30 is acceptable for a pilot study, while (Julious, 2005) suggest a minimum sample of n=12 per group. Therefore, 24 participants will be recruited for this study. This has already been implemented in other pilot studies that sought to identify the efficacy of an intervention using samples of 20 (Berrymam et al., 2020) and 13 participants (Delaney, 2018) in total. Although the size of the sample may be a methodological limitation, it will be considered in the discussion of the results; in addition to being a preliminary study to carry out a more rigorous study with an RCT. Participants will be eligible if they are between 20 and 45 years old because 77.5% of the reported cases are in this age range in Mexico (CENSIDA, 2022) .

The procedure will be as follows: All participants will be explained what the study consists of, the intervention and will be given informed consent. Patients will be recruited from the Specialized Clinic Condesa Iztapalapa that serves people living with HIV. A brief medical history will begin with an interview to collect medical history (HIV pathological and infectious history such as time of evolution, viral load, CD4 level, ART regimen, as well as substance abuse and cognitive complaints) and then a neuropsychological assessment will be performed. With those candidates who meet the inclusion criteria and wish to participate, will be randomly assigned in a 1:1 ratio to the intervention group or waiting list control arm. The intervention will begin first with the study group, and a subsequent evaluation will be carried out and then the intervention will be applied to the control group on the waiting list, which will also undergo a subsequent evaluation. Both groups will undergo a third follow-up evaluation three months later to identify whether the changes were maintained over time. Main outcomes of interest include evaluation of the achievement of intervention objectives, usability and acceptability of the CSP. Baseline and follow up measures include assessment of attention, memory, visuospatial skills, working memory, processing speed, verbal fluency, planning, abstraction, depressive and anxiety symptomatology, and daily functionality.

02

Conditions studied

  • Telerehabilitation
  • Neuropsychology
  • HIV Dementia

Browse trials for

Keywords

  • HIV
  • HAND
  • Teleneuropsychological intervention
03

In context

AIDS Dementia Complex

41 studies on the registry are indexed under AIDS Dementia Complex; 2 are open to participants now.

Browse AIDS Dementia Complex studies →

Lead sponsor

Universidad Nacional Autonoma de Mexico is the lead sponsor of 28 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or females with
  • Minimum primary education
  • From 20 to 45 years old
  • Normal or corrected vision and hearing
  • Treatment adherence

Exclusion criteria

Exclusion Criteria:

  • Neurological and psychiatric history (except mood disorders)
  • Head injuries
  • Cerebrovascular events
  • Substance abuse
  • AIDS associated diseases
  • Hormonal therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Study group

    Refers to the experimental group that will receive the cognitive stimulation program intervention.

    Behavioral: Cognitive stimulation program

  • Other
    Waiting list control group

    Will be the control group that remains without intervention until the study group completes the cognitive stimulation program and the subsequent neuropsychological assessment has been done. Once the intervention is completed with the study group, the same program will be applied to the control group.

    Behavioral: Cognitive stimulation program

Interventions

  • BehavioralCognitive stimulation program

    The cognitive stimulation program consists of 12 sessions of approximately 45 minutes, distributed in a first stage of training and psychoeducation (1 session), a second stage to address emotional aspects of anxiety and depression (2 sessions), and neuropsychological training (8 sessions) and a final closing stage with one session. There will be two sessions per week for 6 weeks. The neuropsychological training includes 20 activities whose level of difficulty will vary according to the number of stimuli and the time of stimuli presentation. It includes 5 attentional activities, 3 memory activities, 5 executive functioning activities, one visuospatial skills activity and 6 ecological activities. These activities will be developed on a digital computer platform where patients will be assigned an identification and password to ensure confidentiality.

    Also known as: N&C NeuroChange

06

What researchers measure

Primary outcomes

  1. Attention

    Direct digits of the Integrated Neuropsychological Exploration Program. The repetition of a series of digits is requested and an element is added as the task progresses. Uses percentile scores.

    Time frame: Baseline

  2. Memory

    Immediate and deferred texts, and word learning of the Integrated Neuropsychological Exploration Program. Two stories are read and at the end of each one, the patient is asked to narrate everything he/she remembers from the story. In case of not remembering elements, questions are asked about the missing information. The stories are asked again after 5 minutes. Uses percentile scores.

    Time frame: Baseline

  3. Visuospatial skills

    Rey Figure of the NEUROPSI A\&M. A complex figure is copied from a model. Afterwards, the figure is drawn again without the model. Uses scalar scores.

    Time frame: Baseline

  4. Working memory

    Digits and letters of the Weschler Adults Intelligence Scale IV. Numbers and letters are provided in disorder and all the elements are asked to be repeated in order, first the numbers and then the letters. Uses scalar scores.

    Time frame: Baseline

  5. Processing speed

    Word reading of Stroop test. A list of 5 columns of words with 20 items each is read as quickly as possible. Uses percentile scores.

    Time frame: Baseline

  6. Verbal fluency

    Categorical recall of the Integrated Neuropsychological Exploration Program. The highest number of animals is said in one minute and the highest number of words beginning with "p" in three minutes. Uses percentile scores.

    Time frame: Baseline

  7. Planning

    Zoo test of the Behavioral Assessment of Dysexecutive Syndrome and Behavioral Rating Inventory of Executive Functioning for Adults. Consists in marking a route in a zoo map to visit different places. Afterwards, the person marks again in the zoo map a rout but is told which route to follow.

    Time frame: Baseline

  8. Abstraction

    Resemblances of the Weschler Adults Intelligence Scale IV. Consists in mentioning what two words have in common or how they are similar. Uses scalar scores.

    Time frame: Baseline

  9. Attention

    Direct digits of the Integrated Neuropsychological Exploration Program. The repetition of a series of digits is requested and an element is added as the task progresses. Uses percentile scores.

    Time frame: Immediately after the intervention

  10. Memory

    Immediate and deferred texts, and word learning of the Integrated Neuropsychological Exploration Program. Two stories are read and at the end of each one, the patient is asked to narrate everything he/she remembers from the story. In case of not remembering elements, questions are asked about the missing information. The stories are asked again after 5 minutes. Uses percentile scores.

    Time frame: Immediately after the intervention

  11. Visuospatial skills

    Rey Figure of the NEUROPSI A\&M. A complex figure is copied from a model. Afterwards, the figure is drawn again without the model. Uses scalar scores.

    Time frame: Immediately after the intervention

  12. Working memory

    Digits and letters of the Weschler Adults Intelligence Scale IV. Numbers and letters are provided in disorder and all the elements are asked to be repeated in order, first the numbers and then the letters. Uses scalar scores.

    Time frame: Immediately after the intervention

  13. Processing speed

    Word reading of Stroop test. A list of 5 columns of words with 20 items each is read as quickly as possible. Uses percentile scores.

    Time frame: Immediately after the intervention

  14. Verbal fluency

    Categorical recall of the Integrated Neuropsychological Exploration Program. The highest number of animals is said in one minute and the highest number of words beginning with "p" in three minutes. Uses percentile scores.

    Time frame: Immediately after the intervention

  15. Planning

    Zoo test of the Behavioral Assessment of Dysexecutive Syndrome and Behavioral Rating Inventory of Executive Functioning for Adults. Consists in marking a route in a zoo map to visit different places. Afterwards, the person marks again in the zoo map a rout but is told which route to follow.

    Time frame: Immediately after the intervention

  16. Abstraction

    Resemblances of the Weschler Adults Intelligence Scale IV. Consists in mentioning what two words have in common or how they are similar. Uses scalar scores.

    Time frame: Immediately after the intervention

  17. Attention

    Direct digits of the Integrated Neuropsychological Exploration Program. The repetition of a series of digits is requested and an element is added as the task progresses. Uses percentile scores.

    Time frame: Up to 12 weeks

  18. Memory

    Immediate and deferred texts, and word learning of the Integrated Neuropsychological Exploration Program. Two stories are read and at the end of each one, the patient is asked to narrate everything he/she remembers from the story. In case of not remembering elements, questions are asked about the missing information. The stories are asked again after 5 minutes. Uses percentile scores.

    Time frame: Up to 12 weeks

  19. Visuospatial skills

    Rey Figure of the NEUROPSI A\&M. A complex figure is copied from a model. Afterwards, the figure is drawn again without the model. Uses scalar scores.

    Time frame: Up to 12 weeks

  20. Working memory

    Digits and letters of the Weschler Adults Intelligence Scale IV. Numbers and letters are provided in disorder and all the elements are asked to be repeated in order, first the numbers and then the letters. Uses scalar scores.

    Time frame: Up to 12 weeks

  21. Processing speed

    Word reading of Stroop test. A list of 5 columns of words with 20 items each is read as quickly as possible. Uses percentile scores.

    Time frame: Up to 12 weeks

  22. Verbal fluency

    Categorical recall of the Integrated Neuropsychological Exploration Program. The highest number of animals is said in one minute and the highest number of words beginning with "p" in three minutes. Uses percentile scores.

    Time frame: Up to 12 weeks

  23. Planning

    Zoo test of the Behavioral Assessment of Dysexecutive Syndrome and Behavioral Rating Inventory of Executive Functioning for Adults. Consists in marking a route in a zoo map to visit different places. Afterwards, the person marks again in the zoo map a rout but is told which route to follow.

    Time frame: Up to 12 weeks

  24. Abstraction

    Resemblances of the Weschler Adults Intelligence Scale IV. Consists in mentioning what two words have in common or how they are similar. Uses scalar scores.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Depressive Symptoms

    Patient Health Questionnaire - 9. A self-applied questionnaire that identifies the presence of depressive symptomatology based on a Likert-type scale of 9 items. Based on the cut-off points, minimal (0-4), mild (5-9), moderate (10-14), moderate to severe (15-19) and severe (20-27) depression can be identified.

    Time frame: Baseline

  2. Anxiety symptoms

    General Anxiety Disorder - 7. A self-applied scale to identify generalized anxiety. It consists of a self-applied questionnaire of seven Likert-type questions. Based on the cut-off points, no anxiety (0-4), mild anxiety symptoms (5-9), moderate anxiety symptoms (10-14) and severe anxiety symptoms (15-21) can be identified.

    Time frame: Baseline

  3. Daily functionality

    The Activities of Daily Living Questionnaire. This instrument evaluates daily functioning by assessing basic and instrumental activities in six areas (self-care, home activities, work, recreation, money management, travel and communication, and information technology); it is usually useful for patients with mild cognitive or motor limitations. It allows to generate a percentage of functional impairment by adding the scores of each item among the total number of responses per 100.

    Time frame: Baseline

  4. Depressive Symptoms

    Patient Health Questionnaire - 9. A self-applied questionnaire that identifies the presence of depressive symptomatology based on a Likert-type scale of 9 items. Based on the cut-off points, minimal (0-4), mild (5-9), moderate (10-14), moderate to severe (15-19) and severe (20-27) depression can be identified.

    Time frame: Immediately after the intervention

  5. Anxiety symptoms

    General Anxiety Disorder - 7. A self-applied scale to identify generalized anxiety. It consists of a self-applied questionnaire of seven Likert-type questions. Based on the cut-off points, no anxiety (0-4), mild anxiety symptoms (5-9), moderate anxiety symptoms (10-14) and severe anxiety symptoms (15-21) can be identified.

    Time frame: Immediately after the intervention

  6. Daily functionality

    The Activities of Daily Living Questionnaire. This instrument evaluates daily functioning by assessing basic and instrumental activities in six areas (self-care, home activities, work, recreation, money management, travel and communication, and information technology); it is usually useful for patients with mild cognitive or motor limitations. It allows to generate a percentage of functional impairment by adding the scores of each item among the total number of responses per 100.

    Time frame: Immediately after the intervention

  7. Depressive Symptoms

    Patient Health Questionnaire - 9. A self-applied questionnaire that identifies the presence of depressive symptomatology based on a Likert-type scale of 9 items. Based on the cut-off points, minimal (0-4), mild (5-9), moderate (10-14), moderate to severe (15-19) and severe (20-27) depression can be identified.

    Time frame: Up to 12 weeks

  8. Anxiety symptoms

    General Anxiety Disorder - 7. A self-applied scale to identify generalized anxiety. It consists of a self-applied questionnaire of seven Likert-type questions. Based on the cut-off points, no anxiety (0-4), mild anxiety symptoms (5-9), moderate anxiety symptoms (10-14) and severe anxiety symptoms (15-21) can be identified.

    Time frame: Up to 12 weeks

  9. Daily functionality

    The Activities of Daily Living Questionnaire. This instrument evaluates daily functioning by assessing basic and instrumental activities in six areas (self-care, home activities, work, recreation, money management, travel and communication, and information technology); it is usually useful for patients with mild cognitive or motor limitations. It allows to generate a percentage of functional impairment by adding the scores of each item among the total number of responses per 100.

    Time frame: Up to 12 weeks

Other outcomes

  1. Evaluation of the achievement of intervention objectives

    Goal Assessment Scale. Mathematical technique that identifies the achievement of objectives in a rehabilitation program based on the perception of the patient and/or family member. Each objective is measured on a 5-point scale ranging from -2 to +2 (very little, little, expected level, more than expected, much more than expected).

    Time frame: Baseline

  2. Evaluation of the usability of the cognitive stimulation program

    System usability scale. A 5-level Likert-type scale (strongly disagree to strongly agree) that evaluates the opinion of the participants regarding the usability of digital systems. A maximum total score of 100 is obtained by averaging each response from all questionnaires.

    Time frame: Immediately after the intervention

  3. Evaluation of the acceptability of the cognitive stimulation program

    In the last session of the intervention, a qualitative interview will be conducted with the participants. The interview will include questions associated with the relevance, usefulness, acceptability and satisfaction of the cognitive stimulation program.

    Time frame: Immediately after the intervention

  4. Evaluation of the achievement of intervention objectives

    Goal Assessment Scale. Mathematical technique that identifies the achievement of objectives in a rehabilitation program based on the perception of the patient and/or family member. Each objective is measured on a 5-point scale ranging from -2 to +2 (very little, little, expected level, more than expected, much more than expected).

    Time frame: Immediately after the intervention

07

Study locations

1 site
  • Condesa Iztapalapa Specialized Clinic
    Mexico City, Iztapalapa 09730, Mexico
08

References and documents

Publications

  • Becker JT, Dew MA, Aizenstein HJ, Lopez OL, Morrow L, Saxton J, Tarraga L. A pilot study of the effects of internet-based cognitive stimulation on neuropsychological function in HIV disease. Disabil Rehabil. 2012;34(21):1848-52. doi: 10.3109/09638288.2012.667188. Epub 2012 Mar 30. PubMed 22458375 ↗
  • Bilder RM, Postal KS, Barisa M, Aase DM, Cullum CM, Gillaspy SR, Harder L, Kanter G, Lanca M, Lechuga DM, Morgan JM, Most R, Puente AE, Salinas CM, Woodhouse J. InterOrganizational practice committee recommendations/guidance for teleneuropsychology (TeleNP) in response to the COVID-19 pandemic. Clin Neuropsychol. 2020 Oct-Nov;34(7-8):1314-1334. doi: 10.1080/13854046.2020.1767214. Epub 2020 Jul 16. PubMed 32673163 ↗
  • Boivin MJ, Busman RA, Parikh SM, Bangirana P, Page CF, Opoka RO, Giordani B. A pilot study of the neuropsychological benefits of computerized cognitive rehabilitation in Ugandan children with HIV. Neuropsychology. 2010 Sep;24(5):667-73. doi: 10.1037/a0019312. PubMed 20804255 ↗
  • Vance DE, Fazeli PL, Ross LA, Wadley VG, Ball KK. Speed of processing training with middle-age and older adults with HIV: a pilot study. J Assoc Nurses AIDS Care. 2012 Nov-Dec;23(6):500-10. doi: 10.1016/j.jana.2012.01.005. Epub 2012 May 11. PubMed 22579081 ↗
  • Weber E, Blackstone K, Woods SP. Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action. Neuropsychol Rev. 2013 Mar;23(1):81-98. doi: 10.1007/s11065-013-9225-6. Epub 2013 Feb 16. PubMed 23417497 ↗
  • Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004 May;10(2):307-12. doi: 10.1111/j..2002.384.doc.x. PubMed 15189396 ↗
  • Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics. 2005; 4: 287e91.
  • Berryman A, Rasavage K, Politzer T, Gerber D. Oculomotor Treatment in Traumatic Brain Injury Rehabilitation: A Randomized Controlled Pilot Trial. Am J Occup Ther. 2020 Jan/Feb;74(1):7401185050p1-7401185050p7. doi: 10.5014/ajot.2020.026880. PubMed 32078510 ↗
  • Delaney MC. Caring for the caregivers: Evaluation of the effect of an eight-week pilot mindful self-compassion (MSC) training program on nurses' compassion fatigue and resilience. PLoS One. 2018 Nov 21;13(11):e0207261. doi: 10.1371/journal.pone.0207261. eCollection 2018. PubMed 30462717 ↗

Individual participant data

Plan to share: No — While the results of the present research will be shared in a scientific publication article, there is still no plan to make IPDs available due to the confidentiality that must be maintained when working with HIV+ populations and the ethical issues that remain during the research.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Nov 2023, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2022
First posted
Oct 7, 2022
StartActual
May 16, 2022
Primary completionActual
Nov 28, 2023
CompletionActual
May 30, 2024
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05571761
Lead sponsor
Universidad Nacional Autonoma de Mexico
Responsible party
Natalia Cortés Corona, MD (Principal Investigator, Universidad Nacional Autonoma de Mexico) — Principal investigator
First posted
Oct 7, 2022
Start date
May 16, 2022
Primary completion
Nov 28, 2023
Completion
May 30, 2024
Last update
Jul 3, 2024

Study contacts

Natalia C Cortés, MD
principal investigator · Universidad Nacional Autonoma de Mexico
Ma Guillermina T Yáñez, PhD
study chair · Universidad Nacional Autonoma de Mexico
Dulce María Bélen C Prieto, PhD
study chair · Universidad Nacional Autonoma de Mexico
Edgar R Landa, PhD
study chair · Universidad Nacional Autonoma de Mexico
Juan C Castillo, PhD
study chair · National Polythecnic Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion